Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (PAVM) is a commercial-stage medical technology leader driving innovation in diagnostic testing, medical devices, and digital health solutions. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments, clinical milestones, and strategic initiatives shaping the future of preventive care technologies.
Access official press releases, earnings reports, and regulatory filings in one centralized location. Our curated collection features updates on product commercialization progress, FDA clearances, and partnership announcements, enabling stakeholders to track the company’s execution of its rapid concept-to-market strategy across multiple healthcare sectors.
Key content categories include financial performance updates, new product launches, clinical study results, and executive leadership developments. The resource is particularly valuable for monitoring advancements in PAVmed’s flagship diagnostic tools like the EsoGuard test and digital health platforms through subsidiary Veris Health.
Bookmark this page for streamlined access to verified information directly from corporate communications. Check regularly for updates on PAVmed’s progress in commercializing technologies designed to improve early disease detection and patient care delivery.
PAVmed (NASDAQ: PAVM) will implement a 1-for-30 reverse stock split of its common stock effective January 2, 2026 at 12:01 a.m. ET. The split-adjusted shares will begin trading on Nasdaq under the symbol PAVM at market open on January 2, 2026.
The reverse split is intended to bring the company into compliance with Nasdaq's $1.00 minimum bid requirement. The company's authorized common shares will be reduced from 250,000,000 to 25,000,000. Equity awards, outstanding options, convertible securities, and ESPP allocations will be proportionately adjusted; fractional shares will be rounded up to whole shares. New CUSIP: 70387R502.
Lucid Diagnostics (Nasdaq: LUCD) reported real-world data from an 18-month retrospective analysis of 11,991 at-risk patients who underwent EsoCheck cell collection and EsoGuard DNA testing between January 2023 and June 2024.
Key findings: 95% technical success, 95% of collections completed in under two minutes, and no serious adverse events. Authors concluded the results show safety, tolerability, scalability, and appropriate physician use consistent with prior studies.
Lucid Diagnostics (Nasdaq: LUCD) was named the winner in its company size category in the GenomeWeb 2025 Best Places to Work program on November 20, 2025.
The award recognizes top workplaces across diagnostics and precision medicine for transparent communication, an inclusive environment, professional development, and collaborative culture. Lucid is described as a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM). Company leadership credited employees for the recognition and emphasized a focus on patients, culture, scientific rigor, and long-term commercial success.
Lucid Diagnostics (Nasdaq: LUCD) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 in New York City.
Dennis McGrath, Lucid's Chief Financial Officer, will be available for one-on-one investor meetings; meetings must be scheduled through a Canaccord Genuity representative.
PAVmed (NASDAQ: PAVM) and subsidiaries Lucid Diagnostics (NASDAQ: LUCD) and Veris Health provided a business update and reported 3Q25 results on November 13, 2025. Key operating items: Lucid recognized $1.2M of EsoGuard revenue and processed 2,841 tests, and a Medicare Contractor Advisory Committee meeting showed unanimous expert support for Medicare coverage. Lucid completed an underwritten offering netting approximately $27.0M. Veris launched commercial deployment with OSU James and relaunched development of an implantable physiological monitor ahead of a planned 2026 510(k) submission. Financials: consolidated revenue was $5K for the quarter, GAAP net loss attributable to common stockholders was approximately $6.3M (loss per diluted share $(0.29)), non-GAAP adjusted loss was approximately $0.4M, and cash and cash equivalents totaled $3.1M.
Lucid Diagnostics (Nasdaq: LUCD) reported 3Q25 EsoGuard revenue of $1.2M from 2,841 tests processed, GAAP net loss of $10.4M (GAAP EPS $(0.10)), and non-GAAP adjusted loss of $10.3M ($(0.10) per share).
The company completed a public offering netting $27.0M, ended 3Q25 with $47.3M cash proforma, and said this extends runway through 2026 and past upcoming reimbursement milestones. A MolDx CAC meeting produced a unanimous expert consensus supporting Medicare coverage for EsoGuard, a key step in LCD reconsideration.
PAVmed (NASDAQ: LUCD) will host a business update conference call and webcast on November 13, 2025 at 8:30 AM ET. The call will feature Lishan Aklog, M.D., chairman and CEO, providing an overview of operations and growth strategy, and Dennis McGrath, president and CFO, discussing the company’s third quarter 2025 financial results.
The live webcast will be available in the investor relations section of pavmed.com. U.S. callers can join by dialing 1-800-836-8184; international listeners can dial 1-646-357-8785 and should request the conference name "PAVmed Business Update." A replay will be available on the investor relations website for 30 days after the call.
Lucid Diagnostics (Nasdaq: LUCD) will hold a business update conference call and webcast on Wednesday, November 12, 2025 at 8:30 AM ET. Management will include Lishan Aklog, M.D., chairman and CEO, who will provide a business update and growth strategy overview, and Dennis McGrath, CFO, who will discuss third quarter 2025 financial results. The webcast will be available in the investor relations section at luciddx.com. U.S. dial-in is 1-800-836-8184; international dial-in is 1-646-357-8785; ask the operator for the conference call name "Lucid Diagnostics Business Update" to join. A replay will be available for 30 days on the investor relations site.
Lucid Diagnostics (Nasdaq: LUCD) will participate in the 2025 Maxim Growth Summit in New York City on October 22-23, 2025.
Dennis McGrath, Lucid's Chief Financial Officer, will hold one-on-one investor meetings during the conference; investors should contact their Maxim representative to schedule meetings. Registration and event details are available through the Maxim Growth Summit event page.
PAVmed (Nasdaq: PAVM) subsidiary Veris Health and OSUCCC – James launched the commercial phase of a long‑term strategic partnership on October 7, 2025.
The Veris Cancer Care Platform will be deployed across The James with a clinical registry for enrolled patients, remote physiologic data collection via a VerisBox™, symptom reporting, telehealth, and EHR integration to support personalized cancer care and earlier complication detection.
Veris is also developing an implantable physiological monitor to pair with the platform; no financial terms or timelines were disclosed.
FAQ
What is the current stock price of Pavmed (PAVM)?
What is the market cap of Pavmed (PAVM)?
